Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia

Cancer Cell

Volumn 7, Issue 4, 2005, Pages 375-386

  Lugthart, Sanne ^a,c   Cheok, Meyling H ^a   Den Boer, Monique L ^c   Yang, Wenjian ^a,b   Holleman, Amy ^c   Cheng, Cheng ^a   Pui, Ching Hon ^a,b   Relling, Mary V ^a,b   Janka Schaub, Gritta E ^d   Pieters, Rob ^c   Evans, William E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Pharmacogenetics Anticancer A   (United States)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d Children's University Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; ASPARAGINASE; DAUNORUBICIN; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CROSS RESISTANCE; DISEASE ASSOCIATION; DRUG RESISTANCE; GENE EXPRESSION; GENE IDENTIFICATION; GENOME; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 20244377046     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2005.03.002     Document Type: Article

References (40)

1. B.L. Asselin, S. Kreissman, D.J. Coppola, S.D. Bernal, P.R. Leavitt, R.D. Gelber, S.E. Sallan, and H.J. Cohen Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia J. Pediatr. Hematol. Oncol. 21 1999 6 12
2. T.R. Chauncey Drug resistance mechanisms in acute leukemia Curr. Opin. Oncol. 13 2001 21 26
3. M.H. Cheok, W. Yang, C.H. Pui, J.R. Downing, C. Cheng, C.W. Naeve, M.V. Relling, and W.E. Evans Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells Nat. Genet. 34 2003 85 90
4. M.L. den Boer, R. Pieters, K.M. Kazemier, M.M. Rottier, C.M. Zwaan, G.J. Kaspers, G. Janka-Schaub, G. Henze, U. Creutzig, R.J. Scheper, and A.J. Veerman Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia Blood 91 1998 2092 2098
5. M.L. den Boer, D.O. Harms, R. Pieters, K.M. Kazemier, U. Gobel, D. Korholz, U. Graubner, R.J. Haas, N. Jorch, and H.J. Spaar Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia J. Clin. Oncol. 21 2003 3262 3268
6. W.E. Evans, and M.V. Relling Moving towards individualized medicine with pharmacogenomics Nature 429 2004 464 468
7. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J. Am. Stat. Assoc. 94 1999 496 509
8. D.O. Harms, and G.E. Janka-Schaub Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92 Leukemia 14 2000 2234 2239
9. D.O. Harms, U. Gobel, H.J. Spaar, U.B. Graubner, N. Jorch, P. Gutjahr, and G.E. Janka-Schaub Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92 Blood 102 2003 2736 2740
10. A. Holleman, M.L. den Boer, K.M. Kazemier, G.E. Janka-Schaub, and R. Pieters Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia Blood 102 2003 4541 4546
11. A. Holleman, M.H. Cheok, M.L. den Boer, W. Yang, A.J. Veerman, K.M. Kazemier, D. Pei, C. Cheng, C.H. Pui, and M.V. Relling Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment N. Engl. J. Med. 351 2004 533 542
12. T. Hongo, S. Yajima, M. Sakurai, Y. Horikoshi, and R. Hanada In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia Blood 89 1997 2959 2965
13. Y. Iiboshi, P.J. Papst, S.P. Hunger, and N. Terada L-asparaginase inhibits the rapamycin-targeted signaling pathway Biochem. Biophys. Res. Commun. 260 1999 534 539
14. G.J. Kaspers, L.A. Smets, R. Pieters, C.H. van Zantwijk, E.R. van Wering, and A.J. Veerman Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study Blood 85 1995 751 756
15. G.J. Kaspers, A.J. Veerman, R. Pieters, C.H. van Zantwijk, L.A. Smets, E.R. van Wering, and A. van der Does-van den Berg In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia Blood 90 1997 2723 2729
16. G.J. Kaspers, R. Pieters, C.H. van Zantwijk, E.R. van Wering, A. van der Does-van den Berg, and A.J. Veerman Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs Blood 92 1998 259 266
17. T. Nakashima, M. Kuwano, S. Akiyama, and H. Endo Effect of l-asparaginase and asparagine deprivation on RNA metabolism in mouse leukemia L 5178Y cells in suspension culture Cancer Res. 36 1976 3616 3621
18. R. Pieters, and M.L. den Boer Molecular pharmacodynamics in childhood leukemia Int. J. Hematol. 78 2003 402 413
19. R. Pieters, A.H. Loonen, D.R. Huismans, G.J. Broekema, M.W. Dirven, M.W. Heyenbrok, K. Hahlen, and A.J. Veerman In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions Blood 76 1990 2327 2336
20. R. Pieters, D.R. Huismans, A.H. Loonen, K. Hahlen, A. van der Does-van den Berg, E.R. van Wering, and A.J. Veerman Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia Lancet 338 1991 399 403
21. R. Pieters, M.L. den Boer, M. Durian, G. Janka, K. Schmiegelow, G.J. Kaspers, E.R. van Wering, and A.J. Veerman Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - implications for treatment of infants Leukemia 12 1998 1344 1348
22. C.H. Pui, and W.E. Evans Acute lymphoblastic leukemia N. Engl. J. Med. 339 1998 605 615
23. C.H. Pui, J.M. Boyett, G.K. Rivera, M.L. Hancock, J.T. Sandlund, R.C. Ribeiro, J.E. Rubnitz, F.G. Behm, S.C. Raimondi, and A. Gajjar Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital Leukemia 14 2000 2286 2294
24. C.H. Pui, M.V. Relling, D. Campana, and W.E. Evans Childhood acute lymphoblastic leukemia Rev. Clin. Exp. Hematol. 6 2002 161 180
25. C.H. Pui, M.V. Relling, and J.R. Downing Acute lymphoblastic leukemia N. Engl. J. Med. 350 2004 1535 1548
26. C.H. Pui, J.T. Sandlund, D. Pei, D. Campana, G.K. Rivera, R.C. Ribeiro, J.E. Rubnitz, B.I. Razzouk, S.C. Howard, and M.M. Hudson Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIIIB at St. Jude Children's Research Hospital Blood 104 2004 2690 2696
27. N.L. Ramakers-van Woerden, R. Pieters, A.H. Loonen, I. Hubeek, E. van Drunen, H.B. Beverloo, R.M. Slater, J. Harbott, J. Seyfarth, and E.R. van Wering TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia Blood 96 2000 1094 1099
28. M.E. Ross, X. Zhou, G. Song, S.A. Shurtleff, K. Girtman, W.K. Williams, H.C. Liu, R. Mahfouz, S.C. Raimondi, and N. Lenny Classification of pediatric acute lymphoblastic leukemia by gene expression profiling Blood 102 2003 2951 2959
29. L.B. Silverman, and S.E. Sallan Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment Curr. Opin. Hematol. 10 2003 290 296
30. L.B. Silverman, R.D. Gelber, V.K. Dalton, B.L. Asselin, R.D. Barr, L.A. Clavell, C.A. Hurwitz, A. Moghrabi, Y. Samson, and M.A. Schorin Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01 Blood 97 2001 1211 1218
31. P. Sonneveld Multidrug resistance in haematological malignancies J. Intern. Med. 247 2000 521 534
32. W.A. Stams, M.L. den Boer, H.B. Beverloo, J.P. Meijerink, R.L. Stigter, E.R. van Wering, G.E. Janka-Schaub, R. Slater, and R. Pieters Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL Blood 101 2003 2743 2747
33. J.E. Staunton, D.K. Slonim, H.A. Coller, P. Tamayo, M.J. Angelo, J. Park, U. Scherf, J.K. Lee, W.O. Reinhold, and J.N. Weinstein Chemosensitivity prediction by transcriptional profiling Proc. Natl. Acad. Sci. USA 98 2001 10787 10792
34. J.D. Storey, and R. Tibshirani Statistical significance for genomewide studies Proc. Natl. Acad. Sci. USA 100 2003 9440 9445
35. M.D. Story, D.W. Voehringer, L.C. Stephens, and R.E. Meyn L-asparaginase kills lymphoma cells by apoptosis Cancer Chemother. Pharmacol. 32 1993 129 133
36. M.M. van den Heuvel-Eibrink, P. Sonneveld, and R. Pieters The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia Int. J. Clin. Pharmacol. Ther. 38 2000 94 110
37. E.J. Yeoh, M.E. Ross, S.A. Shurtleff, W.K. Williams, D. Patel, R. Mahfouz, F.G. Behm, S.C. Raimondi, M.V. Relling, and A. Patel Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling Cancer Cell 1 2002 133 143
38. G. Zaza, W. Yang, L. Kager, M. Cheok, J. Downing, C.H. Pui, C. Cheng, M.V. Relling, and W.E. Evans Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis Blood 104 2004 1435 1441
39. H. Zembutsu, Y. Ohnishi, T. Tsunoda, Y. Furukawa, T. Katagiri, Y. Ueyama, N. Tamaoki, T. Nomura, O. Kitahara, and R. Yanagawa Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs Cancer Res. 62 2002 518 527
40. Y. Zhang, and S.A. Berger Increased calcium influx and ribosomal content correlate with resistance to endoplasmic reticulum stress-induced cell death in mutant leukemia cell lines J. Biol. Chem. 279 2003 6507 6516